Skip to main content
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMPH ISIN · US03209R1032 LEI · 54930055TH0ZLSAQMJ38 US Manufacturing
Filings indexed 916 across all filing types
Latest filing 2026-05-14 Investor Presentation
Country US United States of America
Listing US AMPH

About Amphastar Pharmaceuticals, Inc.

https://amphastar.com/

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging medications. Its portfolio includes generic and proprietary injectable, intranasal, and inhalation products. The company specializes in complex medications such as biologics derived from living cells, proteins, and interchangeable biosimilars. Amphastar also develops innovative drug delivery systems and proprietary technological platforms for various routes of administration.

Recent filings

Filing Released Lang Actions
2026 Bank of America Health Care Conference
Investor Presentation Classification · 93% confidence The document is a slide deck presentation titled “2026 Bank of America Health Care Conference” with forward-looking statements, company overview, financial highlights, pipeline details, and strategy—characteristic of an investor presentation rather than an official report, earnings release, or SEC filing. There is no indication that it is a formal regulatory filing or contains audited financial statements itself; it is clearly a presentation prepared for investors and analysts at a conference. Therefore, the correct classification is Investor Presentation (IP).
2026-05-14 English
Q1 26 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and is described as a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended March 31, 2026. It contains detailed financial statements including balance sheets, statements of operations, comprehensive income, stockholders' equity, cash flows, and notes to the financial statements. It also includes management's discussion and analysis, risk factors, legal proceedings, and other comprehensive information typical of a quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 English
Q1 2026 Earnings Presentation
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation from Amphastar Pharmaceuticals dated May 2026. It includes forward-looking statements, company overview, business model, pipeline evolution, R&D focus, proprietary pipeline details, and scientific data on drug candidates. The content is structured as a presentation with slides, charts, and strategic information aimed at investors or stakeholders. It does not contain actual financial statements or regulatory filings such as 10-K or quarterly reports. It is not an earnings release or a regulatory announcement. The presence of forward-looking statements and detailed pipeline and business strategy information aligns with an Investor Presentation (IP). The document length (15,000 characters) and content confirm it is the presentation itself, not just an announcement of a report. Therefore, the appropriate classification is Investor Presentation (IP).
2026-05-07 English
25th Annual Needham Virtual Healthcare Conference
Investor Presentation Classification · 90% confidence The document is a slide presentation for Amphastar Pharmaceuticals at the 25th Annual Needham Virtual Healthcare Conference, containing forward-looking statements, company overview, business model, pipeline details, R&D investment, strategic priorities, and financial charts. This is clearly an investor-facing slide deck focused on strategy, market positioning, and future plans rather than a regulatory filing or earnings release. It matches the definition of an Investor Presentation (IP).
2026-04-14 English
ARS - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
Annual Report
2026-04-13 English
DEF 14A - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
Proxy Solicitation & Information Statement
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.